ReviewInternational journal of molecular sciences2021
The Emerging Role of Presepsin (P-SEP) in the Diagnosis of Sepsis in the Critically Ill Infant: A Literature Review.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Presepsin as a diagnostic biomarker for sepsis across neonates, children, and adults: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Evaluation of umbilical cord blood presepsin in the diagnosis of neonatal early-onset sepsis.Frontiers in pediatrics · 2026Trial
- Critical appraisal of presepsin for diagnosing late-onset sepsis in critically ill neonates.Clinical chemistry and laboratory medicine · 2026Article
- Presepsin Outperforms Conventional Inflammatory Markers in Distinguishing Malignant from Benign Cervical Lymphadenopathy.Journal of clinical medicine · 2026Article
- Study of some biological markers in cord blood of preterm and term infants and their association with neonatal sepsis.Pediatric endocrinology, diabetes, and metabolism · 2025Article
- Crossing Age Boundaries: The Unifying Potential of Presepsin in Sepsis Diagnosis Across Diverse Age Groups.Journal of clinical medicine · 2024Review
- Diagnosis and Management of Neonatal Bacterial Sepsis: Current Challenges and Future Perspectives.Tropical medicine and infectious disease · 2024Review
- Presepsin in Human Milk Is Delivery Mode and Gender Dependent.Nutrients · 2024Article
- Presepsin in Critical Illness: Current Knowledge and Future Perspectives.Diagnostics (Basel, Switzerland) · 2024Review
- Stop in Time: How to Reduce Unnecessary Antibiotics in Newborns with Late-Onset Sepsis in Neonatal Intensive Care.Tropical medicine and infectious disease · 2024Review
- Changing trend of neonatal Ca/P/Mg status in a Chinese population.Translational pediatrics · 2023Article
- Presepsin as a diagnostic marker of sepsis in children and adolescents: a short critical update.Acta bio-medica : Atenei Parmensis · 2023Review
- Lights and Shadows of Sepsis Management: Challenges and Future Perspectives.International journal of molecular sciences · 2023Article
- Cord blood presepsin as a predictor of early-onset neonatal sepsis in term and preterm newborns.Italian journal of pediatrics · 2023Article
- Group BAntibiotics (Basel, Switzerland) · 2023Review
- Future Biomarkers for Infection and Inflammation in Rheumatoid Arthritis.Journal of inflammation research · 2023Review
- Evaluation of presepsin as a diagnostic tool in newborns with risk of early-onset neonatal sepsis.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis causes high rates of morbidity and mortality in NICUs. The estimated incidence varies between 5 and 170 per 1000 births, depending on the social context. In very low birth-weight neonates, the level of mortality increases with the duration of hospitalization, reaching 36% among infants aged 8-14 days and 52% among infants aged 15-28 days. Early diagnosis is the only tool to improve the poor prognosis of neonatal sepsis. Blood culture, the gold standard for diagnosis, is time-consuming and poorly sensitive. C-reactive protein and procalcitonin, currently used as sepsis biomarkers, are influenced by several maternal and fetal pro-inflammatory conditions in the perinatal age. Presepsin is the N-terminal fragment of soluble CD14 subtype (sCD14-ST): it is released in the bloodstream by monocytes and macrophages, in response to bacterial invasion. Presepsin seems to be a new, promising biomarker for the early diagnosis of sepsis in neonates as it is not modified by perinatal confounding inflammatory factors. The aim of the present review is to collect current knowledge about the role of presepsin in critically ill neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.